Does GLP-1 suppress hepatocyte glucose production directly, via fibroblast growth factor 21? (original) (raw)
When GLP-1 hits the liver: a novel approach for insulin resistance and NASH
Detlef Schuppan
AJP: Gastrointestinal and Liver Physiology, 2012
View PDFchevron_right
GLP-2 as Beneficial Factor in the Glucose Homeostasis in Mice Fed a High Fat Diet
S. Baldassano
Journal of Cellular Physiology, 2015
View PDFchevron_right
Fibroblast Growth Factor 21 (FGF21) and Glucagon-Like Peptide 1 Contribute to Diabetes Resistance in Glucagon Receptor-Deficient Mice
Bilal Omar
Diabetes, 2014
View PDFchevron_right
Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects
Murielle Veniant
AJP: Endocrinology and Metabolism, 2009
View PDFchevron_right
Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Martin Kapps, S. Belli
Diabetes, 2013
View PDFchevron_right
Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complications
Luigi Laviola
Diabetes Research and Clinical Practice, 2007
View PDFchevron_right
Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model
samadhan kshirsagar
Drug Research
View PDFchevron_right
Integrated Regulation of Hepatic Metabolism by Fibroblast Growth Factor 21 (FGF21) in Vivo
Ffolliott Fisher
Endocrinology, 2011
View PDFchevron_right
GLP 1 Regulated Intestinal Cell’s Insulin Expression and Selfadaptation before the Onset of Type 2 Diabetes
HARSH PANDEY
Advanced Pharmaceutical Bulletin, 2019
View PDFchevron_right
GLP2: an underestimated signal for improving glycaemic control and insulin sensitivity
S. Baldassano
Journal of Endocrinology, 2016
View PDFchevron_right
Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?
Dawid Szczepankiewicz
Diabetologia, 2013
View PDFchevron_right
Oral administration of a new HRI activator as a new strategy to improve High‐Fat‐Diet‐induced glucose intolerance, hepatic steatosis and hypertriglyceridemia through FGF21
JAVIER PIZARRO DELGADO
British Journal of Pharmacology, 2019
View PDFchevron_right
Interplay between FGF21 and insulin action in the liver regulates metabolism
Kristin Stanford
Journal of Clinical Investigation, 2014
View PDFchevron_right
GLP-1 based therapy for type 2 diabetes
Bernard Portha
European Journal of Pharmaceutical Sciences, 2006
View PDFchevron_right
Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high-fat diet
S. Baldassano
Endocrine, 2016
View PDFchevron_right
Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus
Jens J U U L Holst
Journal of Clinical …, 2009
View PDFchevron_right
Comparative Effects of GLP-1 and GLP-2 on Beta-Cell Function, Glucose Homeostasis and Appetite Regulation
Nigel Irwin, Dawood Khan, Vaibhav Dubey, Asif Ali
Biomolecules, 2024
View PDFchevron_right
Direct effect of GLP-1 infusion on endogenous glucose production in humans
Elza Muscelli
Diabetologia, 2012
View PDFchevron_right
Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes
Yukio Horikawa
FEBS Letters, 2009
View PDFchevron_right
Effect of GLP-1 Treatment on GLUT2 and GLUT4 Expression in Type 1 and Type 2 Rat Diabetic Models
Isabel Valverde
Endocrine, 2001
View PDFchevron_right
Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
Frank Anania
Hepatology, 2010
View PDFchevron_right
Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis
Daniele Nicolini
Liver International, 2011
View PDFchevron_right
Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus
Jens Juul Holst
Clinical Drug Investigation, 2012
View PDFchevron_right
GLP-1: benefits beyond pancreas
A. Faggiano, Angelo Cignarelli, G. Tirabassi, Daniele Santi
Journal of Endocrinological Investigation, 2014
View PDFchevron_right
Defining the Role of GLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade
Jens Juul Holst
Diabetes, 2014
View PDFchevron_right
Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice
Murielle Veniant
Diabetes, 2008
View PDFchevron_right
MECHANISMS IN ENDOCRINOLOGY: Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21
Juan Diez
European Journal of Endocrinology, 2012
View PDFchevron_right
GLP-1 receptor agonists: Targeting both hyperglycaemia and disease processes in diabetes
Jens Juul Holst
Diabetes Research and Clinical Practice, 2009
View PDFchevron_right
Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1
Jens Juul Holst
Diabetes/Metabolism Research and Reviews, 2002
View PDFchevron_right
Preserved GLP-I effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats
ana rubi jimenez alcantara
Diabetes, 1997
View PDFchevron_right
FGF-21 as a novel metabolic regulator
George Sandusky
Journal of Clinical Investigation, 2005
View PDFchevron_right
Pharmacological Targeting of Glucagon and Glucagon-Like Peptide 1 Receptors Has Different Effects on Energy State and Glucose Homeostasis in Diet-Induced Obese Mice
Laszlo Boros
Journal of Pharmacology and Experimental Therapeutics, 2011
View PDFchevron_right
Glucagon-receptor Signaling Regulates Energy Metabolism Via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21
Pepin, Mark E
Diabetes, 2018
View PDFchevron_right